In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Jean-Marc Classe and Florence Joly to discuss the CHRONO trial. Dr. Classe is a surgeon and former head of the surgical department of the Institute of Surgical Oncology of Nantes, France. He is a professor in oncology and president of the French Society of Surgical Oncology. Dr. Joly is a medical oncologist and coordinator of gynecological and genito-urinary medical oncology. She is also the head of the clinical research department of Francois Baclesse Comprehensive Cancer Center in Caen, France. She is a professor in medical oncology and a member of both the scientific board of the GINECO intergroup and the GCIG.



Highlights:

-In patients treated for an advanced ovarian cancer not suitable to primary surgery, the timing of surgery after neoadjuvant chemotherapy (NAC) could depend on chemosensitivity.
-When more cycles of NAC are discussed, do not confuse more cycles in order to make the disease suitable to a complete surgery with more cycles in order to perform less surgery.
-In cases of patients with a highly chemosensitive advanced ovarian cancer, delaying surgery could reduce surgical morbidity and improve quality of life.
-More cycles of NAC to treat a chemosensitive disease could improve the rate of complete surgery and improve the rate of pathological complete response.